Comparison of technical characteristics among the RCIR, RIR, RCR and NRR groups
| Characteristic | RCIR n=46 | RIR n=211 | RCR n=107 | NRR n=588 | P value |
| Lesion location, n (%) | 0.003 | ||||
| ICA | 5 (10.9%) | 20 (9.5%) | 7 (6.5%) | 90 (15.3%) | |
| MCA | 3 (6.5%) | 15 (7.1%) | 15 (14%) | 91 (15.5%) | |
| VA | 19 (41.3%) | 96 (45.5%) | 44 (41.1%) | 201 (34.2%) | |
| BA | 19 (41.3%) | 80 (37.9%) | 41 (38.3%) | 206 (35%) | |
| Mori type, n (%) | 0.769 | ||||
| Mori A | 7 (15.2%) | 36 (17.1%) | 12 (11.3%) | 104 (17.7%) | |
| Mori B | 29 (63%) | 122 (57.8%) | 69 (64.5%) | 343 (58.3%) | |
| Mori C | 10 (21.7%) | 53 (25.1%) | 26 (24.3%) | 141 (24%) | |
| Arterial stenosis (%), median (IQR) | 80 (80–90) | 80 (75–90) | 80 (75–90) | 80 (74.5–90) | 0.990 |
| Residual stenosis, median (IQR) | 10 (0–20) | 10 (5–20) | 10 (10–20) | 10 (5–20) | 0.858 |
| Length of lesion, median (IQR) | 7 (5–9) | 8 (5.5–10) | 7.5 (6–9) | 7 (6–9.6) | 0.724 |
| Length of stent, median (IQR) | 8.5 (8–15) | 13 (8–15) | 9 (8–15) | 9 (8–15) | 0.578 |
| Diameter of stent, median (IQR) | 3.0 (2.5–3.0) | 3.0 (2.5, 3.0) | 3.0 (2.5–3.0) | 3.0 (2.5–3.25) | 0.670 |
| Type of stent, n (%) | 0.848 | ||||
| APOLLO | 26 (56.5%) | 128 (60.7%) | 61 (57%) | 337 (57.3%) | |
| WINGSPAN | 19 (41.3%) | 64 (30.3%) | 37 (34.6%) | 202 (34.4%) | |
| ENTERPRISE | 1 (2.2%) | 14 (6.6%) | 7 (6.5%) | 33 (5.6%) | |
| NEUROFORM EZ | 0 | 5 (2.4%) | 2 (1.9%) | 16 (2.7%) | |
| Perioperative use of Tirofiban, n (%) | 3 (6.5%) | 24 (11.4%) | 9 (8.4%) | 63 (10.7%) | 0.660 |
BA, basilar artery; ICA, internal carotid artery; MCA, middle cerebral artery; NRR, no residual risk; RCIR, residual cholesterol inflammatory risk; RCR, residual cholesterol risk; RIR, residual inflammatory risk; VA, vertebral artery.